Pasithea Therapeutics Corp. (KTTAW)

0.0140 +0.0015 (+12.00%) At close: 04:00PM EDT

Pasithea Therapeutics Corp.

1111 Lincoln Road
Suite 500
Miami Beach, FL 33139
United States
702 514 4174
https://www.pasithea.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 8

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Lawrence Steinman BA, M.D., Ph.D.	Co-Founder, MD & Executive Chairman	250k	N/A	1948
Dr. Tiago Reis Marques M.D., Ph.D.	CEO & Director	480k	N/A	1978
Mr. Daniel H. Schneiderman	Chief Financial Officer	345.94k	N/A	1978
Dr. Graeme Currie Ph.D.	Chief Development Officer	346.62k	N/A	1967
Dr. Yassine Bendiabdallah Ph.D.	COO & Head of UK Clinics	N/A	N/A	1984

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers. Its lead product candidate PAS-004, a next-generation mitogen-activated protein kinase, or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 and Noonan syndrome, as well as lamin A/C cardiomyopathy and oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; PAS-002, for the treatment multiple sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Corporate Governance

Pasithea Therapeutics Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.